Abstract

Background. The aim of the research was to estimate the frequency of the locoregional breast cancer recurrence appearance, the recurrence-free period continuance, and the 3- and 5-year survival depending on the scope of the surgical intervention, menstrual profile, and histological and molecular-biologic characteristics of the primary tumor. Patients and Methods. Among 218 patients with a breast cancer, 99 patients had breast-conserving surgery (BCS) and 119 underwent radical mastectomy (RME); all patients had regional lymphatic nodes dissection. The size and the primary tumor differentiation degree, metastasis presence in the regional lymph nodes, ER expression, PR, and Her/2neu were assessed as the prognostics factors. Results. It was defined that the locoregional recurrence appearance frequency in patients with BCS turned out to be 13%, and in patients after RME it turned out to be 9%; the recurrence-free period continuance was 53 ± 8 months and 56 ± 10 months, respectively. Conclusions. The locoregional cancer recurrence frequency is higher in women with the menstrual function being preserved at the moment of the primary tumor detection than in postmenopausal patients and also in patients having the hyperexpression of the Her/2neu. The ipsilateral cancer recurrence decreases the 3-year survival by 7,1% and the 5-year one by 20,3%, respectively.

Highlights

  • According to the GLOBOCAN 2012 v1.0, in 2012, worldwide there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer. 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths, and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions

  • Maddox et al [2] showed that the overall survival (OS) and disease-free survival (DFS) indices do not essentially differ among the patients who passed the radical mastectomy (RME) on Halsted and the modified mastectomy on Patey

  • The patients were divided into 2 groups: to the first group (n = 99) the patients who underwent the breast-conserving surgery (BCS) were referred, and to the second group (n = 119) we referred the patients who passed RME (RME by Madden: 91 and RME by Patey-Dyson: 28)

Read more

Summary

Introduction

According to the GLOBOCAN 2012 v1.0, in 2012, worldwide there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within 5 years of diagnosis). 57% (8 million) of new cancer cases, 65% (5.3 million) of the cancer deaths, and 48% (15.6 million) of the 5-year prevalent cancer cases occurred in the less developed regions. While choosing between RME and breast-conserving surgery (BCS), the main problem, both to the doctor and to the patient, is to reach the maximum cosmetic result at the minimum local recurrence risk. This is possible only with presence of the tumor occupying up to 25% of the breast size and upon the condition that the “clean” margin of excision is reached. The aim of the research was to estimate the frequency of the locoregional breast cancer recurrence appearance, the recurrence-free period continuance, and the 3- and 5-year survival depending on the scope of the surgical intervention, menstrual profile, and histological and molecular-biologic characteristics of the primary tumor. The ipsilateral cancer recurrence decreases the 3-year survival by 7,1% and the 5-year one by 20,3%, respectively

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call